Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 184

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 184
---
 of natural additives as a safer alternative to opioids. Her dedication extends to her sponsorship of biomedical research and clinical trials, particularly in the area of plant -basedbio -identicalhormone replacement. Ms. Stockwell’s commitment to healthcare innovation is further demonstrated by her membership in the Association for Healthcare Philanthropy (AHP). Ms. Stockwell is also actively involved in advancing the professional development of women in the life sciences through her membership in the BioIndustry Association (BIA), where she focuses on scholarship opportunities. Additionally, she is a member of the National Breast Cancer Coalition, reflecting her commitment to impactful healthcare advocacy. We believe that Ms. Stockwell is well -qualifiedto serve as a director of the Company given her extensive experience and deep knowledge of the healthcare industry and her visionary leadership in healthcare advancements. Glenn Wormanhas been our Chief Financial Officer since July 2024. Mr. Worman has served as Chief Financial Officer of Insight Acquisition Corp., a special purpose acquisition company, since April 2024. Mr. Worman has been a Partner in the New York office of SeatonHill Partners, LP since November 2022. Between 2015 and 2022, Mr. Worman served as the CFO and President of National Holdings Corporation. From 2011 to 2015, he served as the Chief Financial Officer for the Americas for ICAP, plc. Prior to ICAP, plc, Mr. Worman held senior positions at, among other companies, Deutsche Bank, Morgan Stanley, and Merrill Lynch. Mr. Worman is an accomplished and diverse financial services executive with a history of providing strong, effective leadership and developing and executing strategy across a spectrum of businesses. With nearly four decades of experience, he is adept at organizational analysis and implementing change, ensuring proper controls and sources of liquidity are in place, and advising executive management on business direction. Mr. Worman’s prior experience in senior finance and chief operating officer positions in corporate finance, fixed income and equity capital markets, wealth management, investment management, strategic analysis, interdealer brokerage, and compliance underscore his ability to handle industry segment and public company chief financial officer requirements. Mr. Worman earned a BS degree from Ramapo College of New Jersey and an MBA from Fairleigh Dickinson University. Catherine Dowill serve as a member of our board of directors upon the effectiveness of the registration statement of which this prospectus forms a part. Dr. Do was trained as a medical doctor specializing in Public Health and Epidemiology in France, with a keen interest in